ในเมืองไทยมีคุณหมอท่านไหนที่เชี่ยวชาญหรือทำวิจัยเกี่ยวกับโรคนี้อยู่ไหมคะ
และถ้าจขกทอยากจะตรวจ Genetic screening of factor H จะสามารถไปตรวจได้ที่ไหนในเมืองไทยค่ะ
ข้อมูลด้านล่างจากเว็บ
http://www.healthcare.uiowa.edu/kidneeds/
DDD/MPGNII is a rare disease. It is primarily diagnosed in children between 5-15 years of age. The disease is equally represented among sexes. Within 10 years of diagnosis, end-stage renal disease develops in about 50% of these children.
The diagnosis of DDD/MPGNII requires renal biopsy. The biopsy will show dense deposits in the glomerular basement membrane on electron microscopy. Eye problems can develeop and so persons with DDD/MPGNII should see an eye doctor.
The cause of DDD/MPGNII appears to be related to uncontrolled systemic activation of the alternative pathway of the complement cascade.
Most current treatments for DDD/MPGNII are ineffective. However, some persons with DDD/MPGNII do have mutations in a gene called Factor H (CFH). For these patients, plasma exchange can control complement activation and prevent end stage renal disease. Genetic screening of factor H should be offered to all patients with DDD/MPGNII.
เรียนถามผู้รู้ เกี่ยวกับโรคไต Dense deposit disease และ Genetic screening of factor H
และถ้าจขกทอยากจะตรวจ Genetic screening of factor H จะสามารถไปตรวจได้ที่ไหนในเมืองไทยค่ะ
ข้อมูลด้านล่างจากเว็บ
http://www.healthcare.uiowa.edu/kidneeds/
DDD/MPGNII is a rare disease. It is primarily diagnosed in children between 5-15 years of age. The disease is equally represented among sexes. Within 10 years of diagnosis, end-stage renal disease develops in about 50% of these children.
The diagnosis of DDD/MPGNII requires renal biopsy. The biopsy will show dense deposits in the glomerular basement membrane on electron microscopy. Eye problems can develeop and so persons with DDD/MPGNII should see an eye doctor.
The cause of DDD/MPGNII appears to be related to uncontrolled systemic activation of the alternative pathway of the complement cascade.
Most current treatments for DDD/MPGNII are ineffective. However, some persons with DDD/MPGNII do have mutations in a gene called Factor H (CFH). For these patients, plasma exchange can control complement activation and prevent end stage renal disease. Genetic screening of factor H should be offered to all patients with DDD/MPGNII.